RESTRUCTURING EXPENSES |
9 Months Ended |
|---|---|
Sep. 30, 2025 | |
| Restructuring and Related Activities [Abstract] | |
| RESTRUCTURING EXPENSES |
16. RESTRUCTURING EXPENSES
As a result of the established non-coverage for PancraGEN®, the Company announced in the first quarter of 2025 that its board of directors had approved a restructuring and cost-savings plan to reduce operating costs and better align its workforce with the loss of PancraGEN®. In connection with this plan, the Company has incurred $0.7 million in restructuring expenses for the nine months ended September 30, 2025, all of which are severance and related costs. The expenses were paid in the quarter that they were incurred, and the Company has no restructuring liability accrued for as of September 30, 2025. For the three months ended September 30, 2025, the Company did not record any severance costs. For the nine months ended September 30, 2025, the Company recorded $0.5 million in severance costs that were charged to sales and marketing and $0.2 million that were charged to general and administrative expenses in the Company’s consolidated statement of operations.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|